

Vincenzo Di Noia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8143184/publications.pdf>

Version: 2024-02-01

34
papers

694
citations

687335

13
h-index

610883

24
g-index

34
all docs

34
docs citations

34
times ranked

1219
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	3.7	65
2	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
3	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
4	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
5	The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , 2021, 153, 260-264.	2.8	50
6	Transradial versus Transfemoral Access for Hepatic Chemoembolization: Inpatient Prospective Single-Center Study. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1234-1239.	0.5	44
7	Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. <i>Clinical Cancer Research</i> , 2021, 27, 6815-6823.	7.0	44
8	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	3.0	39
9	Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. <i>Vaccines</i> , 2021, 9, 1125.	4.4	37
10	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	1.9	30
11	Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?. <i>Future Oncology</i> , 2018, 14, 919-926.	2.4	29
12	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 599-609.	2.8	20
13	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2019, 20, 82-87.	2.6	19
14	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103404.	4.4	18
15	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 937-945.	3.1	13
16	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 723-728.	3.8	12
17	Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?. <i>Lung Cancer</i> , 2020, 145, 208-210.	2.0	12
18	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	4.2	12

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
20	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	2.4	10
21	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. <i>Future Oncology</i> , 2019, 15, 2349-2360.	2.4	9
22	Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!. <i>European Journal of Cancer</i> , 2022, 165, 169-173.	2.8	9
23	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	2.0	8
24	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 152, 1-6.	2.0	7
25	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360.	2.6	7
26	Are TKIs favourable for the elderly with non-small-cell lung cancer?. <i>Oncotarget</i> , 2016, 7, 46871-46877.	1.8	7
27	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	1.9	5
28	Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar"? Current Treatment Options in <i>Oncology</i> , 2019, 20, 23.	3.0	4
29	Exploring the molecular and biological background of lung neuroendocrine tumours. <i>Journal of Thoracic Disease</i> , 2019, 11, S1194-S1198.	1.4	2
30	The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the "unexplainable". <i>Personalized Medicine</i> , 2018, 15, 319-327.	1.5	2
31	Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S312-S317.	2.8	1
32	Reply to letter entitled: Re: The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey. <i>European Journal of Cancer</i> , 2021, 158, 253-254.	2.8	1
33	Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E4-E9.	1.4	0
34	DEBIRI and capecitabine in refractory prevalently liver metastases of colorectal cancer: A phase II study. <i>Journal of Clinical Oncology</i> , 2015, 33, 724-724.	1.6	0